The general aim of this article is to give a critical interpretation of post-trial obligations towards individual research participants in the Declaration of Helsinki 2013. Transitioning research participants to the appropriate health care when a research study ends is a global problem. The publication of a new version of the Declaration of Helsinki is a great opportunity to discuss it. In my view, the Declaration of Helsinki 2013 identifies at least two clearly different types of post-trial obligations, specifically, access to care after research and access to information after research. The agents entitled to receive post-trial access are the individual participants in research studies. The Declaration identifies the sponsors, researchers and host country governments as the main agents responsible for complying with the post-trial obligations mentioned above. To justify this interpretation of post-trial obligations, I first introduce a classification of post-trial obligations and illustrate its application with examples from post-trial ethics literature. I then make a brief reconstruction of the formulations of post-trial obligations of the Declaration of Helsinki from 2000 to 2008 to correlate the changes with some of the most salient ethical arguments. Finally I advance a critical interpretation of the latest formulation of post-trial obligations. I defend the view that paragraph 34 of 'Post-trial provisions' is an improved formulation by comparison with earlier versions, especially for identifying responsible agents and abandoning ambiguous 'fair benefit' language. However, I criticize the disappearance of 'access to other appropriate care' present in the Declaration since 2004 and the narrow scope given to obligations of access to information after research.

Download full-text PDF

Source
http://dx.doi.org/10.1111/dewb.12099DOI Listing

Publication Analysis

Top Keywords

post-trial obligations
32
declaration helsinki
20
helsinki 2013
12
post-trial
10
obligations declaration
8
critical interpretation
8
interpretation post-trial
8
obligations
8
individual participants
8
obligations access
8

Similar Publications

Non-voluntary BCI explantation: assessing possible neurorights violations in light of contrasting mental ontologies.

J Med Ethics

August 2024

Institute for History and Ethics of Medicine, School of Medicine and Health; School of Social Science and Technology, Technical University of Munich, Munchen, Germany

In research involving patients with implantable brain-computer interfaces (BCIs), there is a regulatory gap concerning post-trial responsibilities and duties of sponsors and investigators towards implanted patients. In this article, we analyse the case of patient R, who underwent non-voluntary explantation of an implanted BCI, causing a discontinuation in her sense of agency and self. To clarify the post-trial duties and responsibilities involved in this case, we first define the ontological status of the BCI using both externalist (EXT) and internalist (INT) theories of cognition.

View Article and Find Full Text PDF

While considerable scholarship has explored responsibilities owed to research participants at the conclusion of explanatory clinical trials, no guidance exists regarding responsibilities owed at the conclusion of a pragmatic clinical trial (PCT). Yet post-trial responsibilities in PCTs present distinct considerations from those emphasized in existing guidance and prior scholarship. Among these considerations include the responsibilities of the healthcare delivery systems in which PCTs are embedded, and decisions about implementation for interventions that demonstrate meaningful benefit following their integration into usual care settings-or deimplementation for those that fail to do so.

View Article and Find Full Text PDF

Post-trial access to implantable neural devices: an exploratory international survey.

BMJ Surg Interv Health Technol

April 2024

School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.

Article Synopsis
  • Clinical trials for neural implants are increasing, but there's a lack of information on participants’ access to devices and care after the trials end.
  • * In a study of 66 trial investigators, most had extensive experience with implantable neural devices and shared insights on post-trial access, identifying barriers like funding and clinical infrastructure.
  • * Despite these challenges, a significant majority of investigators believe there is an ethical duty to ensure participants have access to the devices and ongoing support following trial completion.
View Article and Find Full Text PDF

Patient narratives from two investigational deep brain stimulation trials for traumatic brain injury and obsessive-compulsive disorder reveal that injury and illness rob individuals of personal identity and that neuromodulation can restore it. The early success of these interventions makes a compelling case for continued post-trial access to these technologies. Given the centrality of personal identity to respect for persons, a failure to provide continued access can be understood to represent a metaphorical identity theft.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!